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mutation system.  Results and Conclusions: Compared 
with healthy control subjects, patients with RA showed 
no signifi cant deviations in genotype or allele frequencies 
of TNF-  . The TT homozygosity at codon 10 of TGF-  1 
was signifi cantly higher among patients with bi- or pan-
cytopenia (severe group) than in the patients with anemia 
only (mild group; odds ratio = 6.99, p = 0.003). These fi nd-
ings suggest that the TGF-  1 gene polymorphism in co-
don 10 and the –308 TNF-  gene polymorphism do not 
predispose to the development of RA, but the TGF-  1 
gene polymorphism may affect disease progression. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The myelodysplastic syndrome (MDS) comprises a 
distinct, albeit heterogeneous group of hematopoietic dis-
orders characterized by ineffective hematopoiesis and an 
increased propensity to marrow failure and leukemic 
transformation. The natural history is highly variable. 
The current classiﬁ cation systems of MDS (FAB and 
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 Abstract 
 Objectives: Tumor necrosis factor-  (TNF-  ) and trans-
forming growth factor-  (TGF-  ) are cytokines that play 
key roles in the myelodysplastic syndrome (MDS). There 
have been several reports on the presence of genetic 
polymorphisms in the DNA sequence encoding the lead-
er sequence of the TGF-  1 protein, located in codon 10 in 
exon 1 and in the –308 promoter region of TNF-  . The 
objective of this study was to investigate the association 
between TNF-  and TGF-  1 gene polymorphisms and the 
susceptibility to MDS and the progression of the disease 
among patients with MDS belonging to the refractory 
anemia (RA) subtype.  Methods: The diagnosis of MDS 
(n = 50) was based on the FAB criteria. The TNF-  geno-
types were analyzed by PCR-RFLP and the TGF-  geno-
types were analyzed using an amplifi cation refractory 
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WHO) are based on the morphological features of the bone 
marrow and the blood  [1, 2] . Cytogenetic and molecular 
studies support the concept that the stepwise accumula-
tion of genomic damage in hematopoiesis is central in the 
natural disease course of MDS, but it is generally accepted 
that the hematopoietic microenvironment is also active in 
the hematopoietic failure. Abnormal cytokine production, 
autoreactive T lymphocytes and an altered interaction be-
tween the progenitor cells and the extracellular matrix can 
all promote apoptosis, which has a central role in impaired 
hematopoiesis in MDS. A number of investigators have 
demonstrated an excessive production of proapoptotic cy-
tokines in the bone marrow of MDS patients. Several stud-
ies have stressed the im portance of increased levels of tu-
mor necrosis factor-  (TNF-  ) in the serum and bone mar-
row in promoting apoptosis  [3, 4] . Transforming growth 
factor-  (TGF-  ) is another cytokine which is generally 
considered to be a negative key regulator of hematopoi-
etic stem and progenitor cells  [5–7] . Moreover, one of the 
main new directions in the treatment of MDS is the use 
of compounds which exert inhibitory activity on proapop-
totic cytokines  [8–10] . 
 The regulatory and coding regions of cytokine genes 
are relatively polymorphic and may therefore be useful 
in disease association studies. It has been demonstrated 
that the production of TNF-  or TGF-  1 varies from in-
dividual to individual and partly depends on the poly-
morphisms of these genes. The most widely investigated 
polymorphism of the TNF-  gene is the G ] A transition 
in the –308 promoter region  [11] . It has been shown that 
an A nucleotide at position –308 is associated with in-
creased transcription and production of TNF-   [12, 13] . 
Further, several polymorphisms have been described in 
the TGF-  1 gene, including a T ] C transition at nucleo-
tide 29, in the region encoding the signal sequence, which 
results in a leucine-proline substitution at the 10th amino 
acid  [14] . It has been shown that TT homozygous geno-
types are high TGF-  1 producers  [15–17] . The correla-
tion between the TNF-  gene polymorphism  [18–22] or 
the TGF-  1 gene polymorphism  [23–26] and the disease 
status has been studied in a diverse range of diseases, the 
results suggesting that the gene polymorphisms of TNF-  
or TGF-  may provide a rational indicator of susceptibil-
ity to or prognosis of the disease. Since most of our MDS 
patients belonged to the refractory anemia (RA) subtype, 
in the present study, we have investigated whether a 
TNF-  gene polymorphism in the –308 promoter region 
or a TGF-  1 gene polymorphism in codon 10 are associ-
ated with the development and severity of MDS in pa-
tients belonging to the RA subtype. 
 Patients and Methods 
 Patients 
 Between May 2001 and January 2004, a total of 50 cases with 
RA documented by marrow biopsy were enrolled (12 men and 38 
women, age 72.48  8 1.02 years, range 55–87 years). The diagnosis 
of MDS was based on the FAB criteria  [27] . In 4 of the patients, 
hypoplastic MDS was documented; in all of the other patients, the 
bone marrow was normocellular or hypercellular, satisfying the 
morphologic features of RA according to the FAB and WHO crite-
ria ( ! 5% blasts and  ! 15% ringed sideroblasts). Neither a ﬁ brotic 
form nor secondary MDS was diagnosed. Cytogenetic analysis re-
vealed a normal karyotype in 38 cases, no mitosis in 5 cases, 5q- in 
1 case and 8 chromosome abnormalities in 6 cases. The median 
follow-up was 34.5 months (range: 14–62 months). None of the 
patients had received speciﬁ c therapeutic agents prior to the study. 
They were supported only by red blood cell transfusion. Patients 
were divided into two groups: a mild group comprising patients 
with anemia only (hemoglobin  ! 100 g/l; n = 30), and a severe group 
consisting of patients with bi- or pancytopenia (neutrophil count 
 ! 1 G/l, platelet count  ! 100 G/l; n = 20). Leukemic transformation 
occurred in 3 patients; another 4 patients died due to MDS, without 
leukemic transformation. 
 A control group of 74 healthy blood donors (age, 41.31  8 1.47 
years, range 21–73 years; 32 men and 42 women) was investigated. 
All patients and controls were of adult Hungarian ethnic origin and 
resided in Hungary. 
 This study was performed in accordance with the ethical stan-
dards laid down in the most recent version of the 1964 Declaration 
of Helsinki. The ethical committee of the participating university 
had approved the study. Informed written consent was obtained in 
advance from each of the patients. 
 DNA Extraction 
 Genomic DNA from whole blood containing EDTA was ex-
tracted by a standard technique (High Pure PCR Template Prepa-
ration Kit, Roche Diagnostics, Mannheim, Germany). The analysis 
of the polymorphism was based on polymerase chain reaction tech-
niques performed in a thermal cycler (GeneAmp PCR System 
2700, Applied Biosystems, Foster City, Calif., USA). 
 TNF-  Genotype Assay 
 The G ] A transition at position –308 in the promoter region 
was analyzed by PCR-RFLP  [11] . A single base change at the 3  
 end of primer A1 (underlined) was required for the formation of 
an  Nco I (Fermentas, Vilnius, Lithuania) recognition sequence 
CCATGG (instead of GCATG originally found on the investigated 
gene;  primer A1: 5  -AGGCAATAGGTTTTGAGGGCCAT-3  
and primer A2: 5  -TCCTCCCTGCTCCGAT TCCG-3  )  [11] . The 
reaction mixture of 100   l contained 100 ng of genomic DNA,
20 pmol of the A1 and the A2 primer, respectively, 2.5 U Taq DNA 
polymerase, 1.5 m M MgCl 2,  1 ! PCR Taq polymerase buffer + 
(NH 4 ) 2 SO 4  (Fermentas) and 25 m M of each dNTP (Fermentas). 
The PCR conditions were as follows: initial denaturation at 94  °  C 
for 3 min; 36 cycles at 94  °  C for 1 min, 60  °  C for 1 min and 72  °  C 
for 1 min, and a ﬁ nal extension at 72  °  C for 5 min. The ampliﬁ ed 
product was digested with the endonuclease  Nco I  and analyzed on 
a 12% polyacrylamide gel. The TNF G allele gives two fragments 
of 87 and 20 bp, while the TNF A allele gives a single, 107-bp frag-
ment. 
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 TGF-  Genotype Assay 
 The deﬁ ned single-nucleotide polymorphism T 29 -C in exon 1 of 
the human TGF-  1 gene was determined with an ampliﬁ cation 
refractory mutation system with a generic primer (sense), (5  -TCC-
GTGGGATACTGAGACACC-3  ), and with two allele-speciﬁ c an-
tisense primers, differing from each other in only one base at the 
3  end: primer C: 5  -GCAGCGGTAGCAGCAGCG-3  and primer 
T: 5  -AGCAGCGGTAGCAGCAGCA-3   [28] . The reaction mix-
ture of 50   l contained 100 ng of genomic DNA, 20 pmol of each 
the sense and the antisense primer, 1.25 U Taq DNA polymerase, 
1.5 m M MgCl 2,  1 ! PCR Taq polymerase buffer with (NH 4 ) 2 SO 4 , 
and 25 m M of each dNTP (Fermentas). The thermocycling proce-
dure was as follows: initial denaturation at 94  °  C for 5 min; 35 cycles 
at 94  °  C for 30 s, 60  °  C for 30 s and 72  °  C for 30 s, and a ﬁ nal exten-
sion at 72  °  C for 5 min. The PCR products were analyzed by 1.5% 
agarose (Sigma-Aldrich, St. Louis, Mo., USA) gel electrophoresis. 
The expected size of the speciﬁ c ampliﬁ cation product was 241 bp. 
Samples from 2 known homozygotic individuals and 1 heterozy-
gotic individual, conﬁ rmed by sequencing, were included in each 
reaction. Sequencing was performed with an automated sequencer 
(ABI Prism; Applied Biosystems, Foster City, Calif., USA). 
 Statistical Analysis 
 Statistical analyses for comparisons of allele and genotype fre-
quencies between groups were made using the   2  test, and Fisher’s 
exact test if one cell had n  ! 5. A signiﬁ cance level of p  ! 0.05 was 
considered statistically signiﬁ cant. For comparison of age and sex 
between the patients and the controls, the Mann-Whitney U test 
and Fisher’s exact test were used. Statistical calculations were per-
formed with the GraphPad Prism4 statistical program. 
 The genotype frequencies for each polymorphism were tested 
for deviation from the Hardy-Weinberg equilibrium by means of 
the   2  test, using one degree of freedom. 
 Results 
 The distributions of genotypes and alleles for the dif-
ferent polymorphisms were consistent with those predict-
ed by the Hardy-Weinberg equilibrium in the patients 
and in the controls. The two groups were matching ac-
cording to sex (Fisher’s exact test: p = 0.058), but there 
was a signiﬁ cant difference in the mean age between the 
controls and the patient group (Mann-Whitney U test: 
p  ! 0.01). 
 The –308 Promoter Polymorphism of TNF-  
 The genotypic distribution of the TNF-  gene –308 
promoter G ] A polymorphism is shown in  table 1 . There 
were no signiﬁ cant differences in the TNF-  –308 pro-
moter genotypic distribution between the patients with 
RA (GG, GA and AA = 62.0, 32.0 and 6.0%, respective-
ly) and the healthy controls (GG, GA and AA = 68.9, 28.3 
and 2.8%, respectively). Similarly, there were no differ-
ences in the distribution of TNF-  –308 G ] A genotypes 
between the RA patients with anemia only (mild group; 
GG, GA and AA = 63.3, 33.3 and 3.3%, respectively) and 
those with bi- or pancytopenia (severe group; GG, GA 
and AA = 60.0, 30.0 and 10.0%, respectively) 
 The T 29 -C Polymorphism in Codon 10 of TGF-  1  
 The genotypic distribution of the T 29 -C polymor-
phism of the TGF-  1 gene is shown in  table 2 . No sig-
niﬁ cant difference in genotypic distribution was found 
 Table 1. Distribution of TNF  (–G308A) genotypes in the MDS 
patients belonging to the RA subtype and in the healthy controls 
TNF- (–G308A) genotypes p
GG
n (%)
GA
n (%)
AA
n (%)
Patients with RA (n = 50) 31 (62.0) 16 (32.0) 3 (6.0) 
0.650a    Mild
 (n = 30) 19 (63.3) 10 (33.3) 1 (3.3)
    Severe (n = 20) 12 (60.0) 6 (30.0) 2 (10.0) 
Controls (n = 74) 51 (68.9) 21 (28.3) 2 (2.8)
The mild group comprised patients with anemia only and the 
severe group patients with bi- or pancytopenia.
a 2 = 2.466, d.f. = 4; comparisons between the mild group, the 
severe group and the controls.
 
 Table 2. Distribution of TGF-  T 29 -C (Leu10 ] Pro) genotypes be-
tween the MDS patients belonging to the RA subtype and the 
healthy controls 
TGF- (T29-C) genotypes p
TT
n (%)
CT
n (%)
CC
n (%)
Patients with RA (n = 50) 24 (48.0) 19 (38.0) 7 (14.0) 0.031a
0.007b
0.003c
    Mild (n = 30)  9 (30.0) 16 (53.3) 5 (16.7)
    Severe (n = 20) 15 (75.0)  3 (15.0) 2 (10.0)
Controls (n = 74) 33 (44.6) 28 (37.8) 13 (17.6)
a 2 = 10.58, d.f. = 4; comparisons between the mild group (pa-
tients with anemia only), the severe group (patients with bi- or pan-
cytopenia) and the controls.
b 2 = 9.923, d.f. = 2; statistical analysis was performed between 
the TT and CT + CC genotypes; comparisons between the mild 
group, the severe group and the controls.
c Fischer’s exact test: odds ratio = 6.99; statistical analysis was 
performed between the TT and CT + CC genotypes; comparison 
between the mild group and the severe group.
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between the RA patients overall and the healthy con-
trols. A signiﬁ cant difference was observed, however, 
when the genotypes were taken into consideration with-
in the two subgroups of RA (  2  = 10.58, p = 0.031). To 
elucidate the reason for this signiﬁ cance, we compared 
the number of TT homozygotes (high TGF-  -producing 
phenotype) and C carriers (CT and CC) among the pa-
tients with mild and severe cytopenia forms of RA and 
the healthy controls. A signiﬁ cant difference was ob-
served when the TT homozygotes and C carrier geno-
types were compared within the two subgroups of RA 
together with the healthy controls (  2  = 9.923, p = 0.007). 
There was also a considerable difference in the frequen-
cy of the TT genotype between the two RA subgroups. 
This was due to the overrepresentation of the TT geno-
type in the patients with bi- or pancytopenia [severe 
group; TT = 75.0% (severe) vs. TT = 30.0% (mild), p = 
0.003, odds ratio = 6.99, 95% conﬁ dence interval = 
1.949–25.144]. Alternatively, the C carrier status (rep-
resenting the CT and CC genotypes) was more frequent 
among the RA patients with anemia only (mild group). 
Since we had only 4 patients with the hypoplastic form 
of MDS, it was not meaningful to perform any statistical 
analysis concerning marrow cellularity. Nevertheless, the 
genotypic analysis revealed that 2 of these patients had 
the TT homozygote genotype.  
 Discussion 
 During the past few years, major progress has been 
made toward an understanding of the pathological pro-
cesses of MDS. Genetic abnormalities or altered gene ex-
pressions leading to the suppression of hematopoiesis 
may also be responsible for the development of cytopenia. 
One of the genetic factors may be an aberration of cyto-
kine regulation and cytokine production, which can lead 
to an increased apoptosis of hematopoietic progenitor 
cells, and aberrant hematopoiesis. The excessive produc-
tion of growth-inhibitory cytokines such as TNF-  in pa-
tients with MDS has been described  [3, 4, 29] . Recent 
data indicate that TGF-  inhibits myeloid, erythroid, 
megakaryocytic and multilineage colony formation  [5–
7] . Accordingly, it appeared plausible to hypothesize that 
polymorphisms of the TNF-   [30] or TGF-  1 genes may 
be correlated with MDS or the severity of the disease. 
 In our study, however, no signiﬁ cant difference in the 
–308 TNF-  polymorphism was observed regarding the 
G or A alleles when the forms of RA were compared with 
each other or with the controls. 
 TNF-  also has an apoptotic effect toward hematopoi-
etic cells. However, the distribution of the –308 TNF gene 
polymorphism was similar among the patients in the two 
RA subgroups. Comparison of the genotype frequencies 
in the patients with RA suggests that the –308 G/A poly-
morphism of TNF-  does not affect susceptibility to the 
disease. Within the limits of the currently available evi-
dence, we presume that this polymorphism determining 
TNF-  secretion might be minimized through the secre-
tion of other factors in MDS. There are several potential 
reasons for failing to observe any association between the 
–308 TNF-  polymorphism and RA. The –308 TNF-  
polymorphism would appear to occur at a transcription 
factor binding site in the TNF-  promoter and hence af-
fects protein binding, thereby altering transcriptional ac-
tivity. The transcriptional and translational regulation 
and prosttranslational protein processing are major steps 
involved in protein expression. TNF protein expression 
is probably not exclusively regulated at the transcription-
al level. In complex biological systems, the effect of a 
single gene polymorphism determining cytokine secre-
tion may be minimized through the interaction of other 
factors. 
 TGF-  isoforms are translated as prepropeptide pre-
cursors with an N-terminal signal peptide followed by the 
prodomain and mature domain, and are secreted as bio-
logically latent forms. The Leu10 ] Pro-(T 29 -C) polymor-
phism in exon 1 of the TGF-  1 gene is located in the 
signal peptide sequence that is cleaved from the TGF-  1 
precursor at the level of codon 10  [31] . This polymor-
phism at codon 10 (within the hydrophobic   -helix of the 
signal sequence) involves the replacement of a hydropho-
bic leucine residue with a small, neutral proline residue. 
Such a change would alter the overall hydrophobicity of 
the core transport sequence and disrupt the   -helical 
structure of the region, thereby altering its ability to direct 
protein transport across the endoplasmatic reticulum 
 [14] . The T 29- C polymorphism of the TGF-  1 gene does 
not result in a difference in the mature TGF-  1 protein; 
merely the TGF-  1 protein level is reduced both in vitro 
and in vivo  [15–17] . 
 On the other hand, Yokota et al.  [32]  reported that the 
T allele of T 29 -C was linked to a lower production of TGF-
  1. The inﬂ uence of the allele at codon 10 on TGF-  pro-
duction is possibly more variable, due to the cross-modu-
lating interfaces between the signaling networks within 
the cells. In this study, we have shown that in patients 
with RA the TGF-  ‘high-producer genotype’ TT causes 
a 6.99-fold increased risk of bi- or pancytopenia com-
pared with the C-carriers. Patients carrying the C ‘protec-
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tive’ allele, with a concomitantly lower TGF-  1 produc-
tion, have only anemia. As TGF-  1 is a member of the 
proapoptotic cytokines, it is very likely that patients with 
the low-producing genotypes (CC and CT) may have a 
better chance of a less severe cytopenia in MDS. Although 
we could not ﬁ nd genotypic differences between the RA 
patients overall and the healthy controls, we observed 
that the genotype of the TGF-  1 T 29 -C gene differed sig-
niﬁ cantly between the severe group and the mild group. 
Although the mean age of the study groups was signiﬁ -
cantly different, it is unlikely that this age difference 
would introduce bias into the study because signiﬁ cant 
differences in the distribution of TGF-  genotypes were 
only found among the RA subgroups. These ﬁ ndings in-
dicate that the polymorphism of the TGF-  T 29 -C gene 
itself is not directly involved in the susceptibility to RA, 
but rather affects the outcome of the disease. 
 Overall, the polymorphism in the TNF-  gene in the 
–308 promoter region does not have a principal role in 
the regulation of the outcome of RA patients. In contrast, 
our ﬁ ndings of an association between the severe form of 
RA and TT homozygosity suggest that future studies 
should focus on the role of TGF-  in RA, and further in-
dependent studies with more patients are needed to con-
ﬁ rm our observations. Following these pilot experiments, 
further investigations on the polymorphisms of the TGF-
  1 genes should be included in these investigations . 
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